thalidomide has been researched along with Proteinuria in 13 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Proteinuria: The presence of proteins in the urine, an indicator of KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| " On arrival, laboratory test results were significant for hypokalemia, hyperchloremic metabolic acidosis, low uric acid concentration, positive urine anion gap, and proteinuria, which resolved on discontinuation of the drug." | 7.85 | Proximal Renal Tubular Acidosis (Fanconi Syndrome) Induced by Apremilast: A Case Report. ( Afridi, F; Kar, P; King-Morris, K; Komarla, A; Perrone, D, 2017) |
| "A 62 year-old Caucasian man with hypertension and a 4-year history of multiple myeloma, had been previously treated with lenalidomide, bortezomib and two autologous hematopoietic stem cell transplants." | 7.80 | Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma. ( Hobeika, L; Self, SE; Velez, JC, 2014) |
| "Thalidomide is an effective therapy for multiple myeloma, although its mechanisms of action remain unclear." | 6.71 | Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. ( Berk, JL; Choufani, EB; Dember, LM; Falk, RH; Fennessey, S; Finn, KT; O'Hara, C; Sanchorawala, V; Seldin, DC; Skinner, M; Wiesman, JF; Wright, DG, 2003) |
| "The impact of high dose dexamethasone containing regimens with or without the novel agents thalidomide and bortezomib on the reversal of renal failure (RF) was evaluated in 41 consecutive newly diagnosed patients with multiple myeloma (MM) treated in a single institution." | 5.12 | Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. ( Anagnostopoulos, A; Bamias, A; Barmparousi, D; Dimopoulos, MA; Gika, D; Grapsa, I; Kastritis, E; Matsouka, C; Psimenou, E; Roussou, M, 2007) |
| " On arrival, laboratory test results were significant for hypokalemia, hyperchloremic metabolic acidosis, low uric acid concentration, positive urine anion gap, and proteinuria, which resolved on discontinuation of the drug." | 3.85 | Proximal Renal Tubular Acidosis (Fanconi Syndrome) Induced by Apremilast: A Case Report. ( Afridi, F; Kar, P; King-Morris, K; Komarla, A; Perrone, D, 2017) |
| "A 62 year-old Caucasian man with hypertension and a 4-year history of multiple myeloma, had been previously treated with lenalidomide, bortezomib and two autologous hematopoietic stem cell transplants." | 3.80 | Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma. ( Hobeika, L; Self, SE; Velez, JC, 2014) |
| "In comparison with untreated mice, mice treated with 10 mg/kg of thalidomide monotherapy showed a significant decrease in proteinuria and significantly lower glomerular and tubular damage scores, comparable to 5 or 10 mg/kg of thalidomide plus PL or MMF plus PL." | 3.78 | Attenuation of nephritis in lupus-prone mice by thalidomide. ( Choi, KH; Kim, BS; Lee, SK; Lee, SW; Park, KH; Park, YB; Yang, J, 2012) |
| "Thalidomide is an effective therapy for multiple myeloma, although its mechanisms of action remain unclear." | 2.71 | Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. ( Berk, JL; Choufani, EB; Dember, LM; Falk, RH; Fennessey, S; Finn, KT; O'Hara, C; Sanchorawala, V; Seldin, DC; Skinner, M; Wiesman, JF; Wright, DG, 2003) |
| "We herein present a case of multiple myeloma with Fanconi syndrome and acute kidney injury due to light chain proximal tubulopathy with light chain cast nephropathy." | 1.40 | Acquired Fanconi syndrome with proximal tubular cytoplasmic fibrillary inclusions of λ light chain restriction. ( Liu, G; Liu, L; Wang, SX; Wang, Y; Yao, Y; Zhang, YK, 2014) |
| "The authors have reviewed the treatment of multiple myeloma including the novel agents, thalidomide, bortezomib and lenalidomide." | 1.37 | History of multiple myeloma. ( Kyle, RA; Steensma, DP, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 9 (69.23) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Sapet, M | 1 |
| Fouillet, L | 1 |
| Daguenet, E | 1 |
| Laurent, B | 1 |
| Guyotat, D | 1 |
| Le Jeune, C | 1 |
| Perrone, D | 1 |
| Afridi, F | 1 |
| King-Morris, K | 1 |
| Komarla, A | 1 |
| Kar, P | 1 |
| Yao, Y | 1 |
| Wang, SX | 1 |
| Zhang, YK | 1 |
| Wang, Y | 1 |
| Liu, L | 1 |
| Liu, G | 1 |
| Gkotzamanidou, M | 1 |
| Terpos, E | 1 |
| Kastritis, E | 2 |
| Dimopoulos, MA | 2 |
| Hobeika, L | 1 |
| Self, SE | 1 |
| Velez, JC | 1 |
| Cohen, C | 1 |
| Royer, B | 1 |
| Javaugue, V | 1 |
| Szalat, R | 1 |
| El Karoui, K | 1 |
| Caulier, A | 1 |
| Knebelmann, B | 1 |
| Jaccard, A | 1 |
| Chevret, S | 1 |
| Touchard, G | 1 |
| Fermand, JP | 1 |
| Arnulf, B | 1 |
| Bridoux, F | 1 |
| Kyle, RA | 1 |
| Steensma, DP | 1 |
| Alexander, MP | 1 |
| Nasr, SH | 1 |
| Watson, DC | 1 |
| Méndez, GP | 1 |
| Rennke, HG | 1 |
| Lee, SW | 1 |
| Park, YB | 1 |
| Yang, J | 1 |
| Park, KH | 1 |
| Lee, SK | 1 |
| Choi, KH | 1 |
| Kim, BS | 1 |
| Locke, FL | 1 |
| Morgan, GJ | 1 |
| Seldin, DC | 1 |
| Choufani, EB | 1 |
| Dember, LM | 1 |
| Wiesman, JF | 1 |
| Berk, JL | 1 |
| Falk, RH | 1 |
| O'Hara, C | 1 |
| Fennessey, S | 1 |
| Finn, KT | 1 |
| Wright, DG | 1 |
| Skinner, M | 1 |
| Sanchorawala, V | 1 |
| McGowan, N | 1 |
| Anagnostopoulos, A | 1 |
| Roussou, M | 1 |
| Gika, D | 1 |
| Matsouka, C | 1 |
| Barmparousi, D | 1 |
| Grapsa, I | 1 |
| Psimenou, E | 1 |
| Bamias, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Study of Thalidomide, Bendamustine and Dexamethasone (BTD) Versus Bortezomib, Bendamustine and Dexamethasone (BBD) in Patients With Renal Failure Defined as a GFR Below 30 Mls/Min[NCT02424851] | Phase 2 | 31 participants (Actual) | Interventional | 2014-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT02424851)
Timeframe: End of week 6 (after receiving two cycles of therapy)
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A (BBD) | 13 |
| Arm B (BTD) | 3 |
(NCT02424851)
Timeframe: 1 month post end of treatment and 1 year post randomisation
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A (BBD) | 9 |
| Arm B (BTD) | 13 |
(NCT02424851)
Timeframe: End of weeks 3, 6, 9, 12 (after receiving 4 cycles of therapy), 30 days after final treatment and 12 months after randomisation
| Intervention | Events (Number) | |
|---|---|---|
| Serious adverse events | Adverse events | |
| Arm A (BBD) | 2 | 3 |
| Arm B (BTD) | 0 | 6 |
"The EQ-5D-3L descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension is scored on a scale of 1 to 3: 1 (no problems), 2 (some problems), and 3 (extreme problems). Higher score equates to a worse outcome.~As stated in the official EQ-5D user guide, patient responses to the 5 questions were converted into a single index value as per Dolan P (1997). Modeling valuations for EuroQol health states. Med Care 35(11):1095-108. These index values, with country specific value sets, facilitate the calculation of quality-adjusted life years (QALYs) that are used to inform economic evaluations of health care interventions. In the UK, the values range from -0.594 to +1." (NCT02424851)
Timeframe: Baseline and 1 month follow up
| Intervention | Units on a scale (Mean) | |
|---|---|---|
| Baseline | 1 month FU | |
| Arm A (BBD) | 0.72 | 0.69 |
| Arm B (BTD) | 0.69 | 0.80 |
(NCT02424851)
Timeframe: End of 2nd treatment cycle, week 6
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Partial response | Minor response | No repsonse | |
| Arm A (BBD) | 2 | 9 | 4 |
| Arm B (BTD) | 0 | 7 | 6 |
3 reviews available for thalidomide and Proteinuria
| Article | Year |
|---|---|
Renal crescentic alpha heavy chain deposition disease: a report of 3 cases and review of the literature.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cuti | 2011 |
What is the evidence for the use of bisphosphonate therapy in newly diagnosed multiple myeloma patients lacking bone disease?
Topics: Bone Diseases; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Fatigue; Fractures, Bone; H | 2012 |
What's wrong with this patient? Primary systemic amyloidosis.
Topics: Aged; Amyloidosis; Anti-Inflammatory Agents; Dexamethasone; Diagnosis, Differential; Disease Progres | 2006 |
2 trials available for thalidomide and Proteinuria
| Article | Year |
|---|---|
Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis.
Topics: Adult; Aged; Amyloidosis; Female; Humans; Immunoglobulin Light Chains; Immunosuppressive Agents; Mal | 2003 |
Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bence Jones Protein; | 2007 |
8 other studies available for thalidomide and Proteinuria
| Article | Year |
|---|---|
[Proteinuria in multiple myeloma: Be careful to iatrogeny].
Topics: Aged; Antineoplastic Agents; Autografts; Biopsy; Bortezomib; Dexamethasone; Female; Glomeruloscleros | 2020 |
Proximal Renal Tubular Acidosis (Fanconi Syndrome) Induced by Apremilast: A Case Report.
Topics: Acidosis; Acidosis, Renal Tubular; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriat | 2017 |
Acquired Fanconi syndrome with proximal tubular cytoplasmic fibrillary inclusions of λ light chain restriction.
Topics: Acute Kidney Injury; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acid | 2014 |
Hematologic response and stabilization of renal function in a patient with light chain deposition disease after lenalidomide treatment: a novel therapeutic approach?
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Fatig | 2014 |
Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
Topics: Acute Kidney Injury; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic | 2014 |
Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; D | 2015 |
History of multiple myeloma.
Topics: Adrenal Cortex Hormones; Alkylating Agents; Bence Jones Protein; Boronic Acids; Bortezomib; History, | 2011 |
Attenuation of nephritis in lupus-prone mice by thalidomide.
Topics: Animals; Anti-Inflammatory Agents; Antigen-Antibody Complex; DNA; Dose-Response Relationship, Drug; | 2012 |